Most patients with locally advanced breast cancer (LABC) will require a modified radical mastectomy, a procedure that remains the standard surgical treatment for operable locally advanced disease. Less extensive surgeries are being increasingly explored with the use of neoadjuvant chemotherapy (NACT). The down-staging of tumors seen in these cases not only makes them operable but also, on many occasions can be considered for breast conservative therapy (BCT). Neoadjuvant chemotherapy, is performed prior to breast cancer surgery and offers several advantages over standard postoperative chemotherapy. It is important to know early; if the drug chosen will be effective or not. Recently hydrogen 1 (H1) MR spectroscopy is used to detect and monitor breast cancer through measuring tCho concentration and so predicting response to chemotherapy as early as 24 hours